The enhanced activity observed with the combination of CAZ/AVI and ATM, compared to either agent alone, is promising and requires us to carefully consider the combination of CAZ/AVI and ATM as a new therapeutic option to treat infections caused by highly resistant Enterobacterals strains. Here, ATM is linked to infection.